Share-based Payment Arrangement, Expense of Autolus Therapeutics plc from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Autolus Therapeutics plc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Autolus Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,835,000, a 4.6% decline year-over-year.
  • Autolus Therapeutics plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $17,228,000, a 38% increase year-over-year.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2024 was $15,472,000, a 38% increase from 2023.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2023 was $11,204,000, a 6.7% decline from 2022.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $12,014,000, a 21% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Autolus Therapeutics plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $17,228,000 $3,835,000 -$185,000 -4.6% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $17,413,000 $4,293,000 +$1,358,000 +46% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $16,055,000 $2,867,000 +$583,000 +26% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $15,472,000 $6,233,000 +$2,977,000 +91% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $12,495,000 $4,020,000 +$1,156,000 +40% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $11,339,000 $2,935,000 +$267,000 +10% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $11,072,000 $2,284,000 -$132,000 -5.5% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $11,204,000 $3,256,000 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $2,864,000 -$473,000 -14% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $2,668,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $2,416,000 01 Jan 2023 31 Mar 2023 10-Q 17 May 2024 2024 Q1
Q3 2022 $3,337,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q1 2021 $13,116,000 $670,000 -$6,905,000 -111% 01 Jan 2021 31 Mar 2021 6-K 06 May 2021 2021 Q1
Q4 2020 $20,021,000 $4,236,000 -$2,210,000 -34% 01 Oct 2020 31 Dec 2020 20-F 07 Mar 2023 2022 FY
Q3 2020 $22,231,000 $4,245,000 -$3,464,000 -45% 01 Jul 2020 30 Sep 2020 6-K 05 Nov 2020 2020 Q3
Q2 2020 $25,695,000 $5,305,000 -$3,561,000 -40% 01 Apr 2020 30 Jun 2020 6-K 06 Aug 2020 2020 Q2
Q1 2020 $29,256,000 $6,235,000 -$1,130,000 -15% 01 Jan 2020 31 Mar 2020 6-K 06 May 2021 2021 Q1
Q4 2019 $30,386,000 $6,446,000 +$3,053,000 +90% 01 Oct 2019 31 Dec 2019 20-F 10 Mar 2022 2021 FY
Q3 2019 $27,333,000 $7,709,000 01 Jul 2019 30 Sep 2019 6-K 05 Nov 2020 2020 Q3
Q2 2019 $8,866,000 +$6,490,000 +273% 01 Apr 2019 30 Jun 2019 6-K 06 Aug 2020 2020 Q2
Q1 2019 $7,365,000 01 Jan 2019 31 Mar 2019 6-K 07 May 2020 2020 Q1
Q4 2018 $3,393,000 01 Oct 2018 31 Dec 2018 20-F 04 Mar 2021 2020 FY
Q2 2018 $2,376,000 01 Apr 2018 30 Jun 2018 6-K 08 Aug 2019 2019 Q2

Autolus Therapeutics plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,472,000 +$4,268,000 +38% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $11,204,000 -$810,000 -6.7% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $12,014,000 +$2,077,000 +21% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $9,937,000 -$10,084,000 -50% 01 Jan 2021 31 Dec 2021 10-K 21 Mar 2024 2023 FY
2020 $20,021,000 -$10,365,000 -34% 01 Jan 2020 31 Dec 2020 20-F 07 Mar 2023 2022 FY
2019 $30,386,000 +$23,621,000 +349% 01 Jan 2019 31 Dec 2019 20-F 10 Mar 2022 2021 FY
2018 $6,765,000 +$3,612,000 +115% 01 Oct 2017 30 Sep 2018 20-F 03 Mar 2020 2019 FY
2017 $3,153,000 +$896,000 +40% 01 Oct 2016 30 Sep 2017 20-F 03 Mar 2020 2019 FY
2016 $2,257,000 01 Oct 2015 30 Sep 2016 20-F 25 Feb 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.